ClinicalTrials.gg
RecruitingNCT07638358BCPARPBVUpdated Jun 11, 2026

Assessment of the Impact of Neobone® (Biphasic Calcium Phosphate) on Bone Volume in Alveolar Ridge Preservation After Tooth Extraction

An Early Phase 1 interventional study of Neobone® (Biphasic Calcium Phosphate) in Tooth Extraction Site Healing and Alveolar Ridge Preservation, sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL. Recruiting at 1 site in Portugal. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Egas Moniz - Cooperativa de Ensino Superior, CRL · Early Phase 1, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Dec 2025, registered Jun 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this randomized clinical trial is to assess whether BCP (Biphasic Calcium Phosphate) improves alveolar ridge preservation (ARP) in patients who need tooth extraction. The main question it aims to answer is whether using BCP for alveolar ridge preservation has a positive effect on bone volume compared with natural healing.

The main questions it aims to answer are:

Does BCP improve ridge preservation compared with natural healing?

Researchers will compare BCP grafted sockets to natural healing sockets to see if BCP better preserves ridge volume.

Participants will:

Have a tooth indicated for extraction.

Be assigned to either BCP or natural healing.

Undergo CBCT (Cone Beam Computed Tomography) and intra-oral scanning after extraction and after six months of healing to measure horizontal and vertical resorption and bone density.

02

Conditions studied

  • Tooth Extraction Site Healing
  • Alveolar Ridge Preservation

Keywords

  • Alveolar Ridge Preservation
  • Biphasic Calcium Phosphate
  • Tooth Extraction
  • Volumetric Changes
  • Implant site development
  • Bone volume
  • Socket preservation
  • Ridge augmentation
03

In context

Lead sponsor

Egas Moniz - Cooperativa de Ensino Superior, CRL is the lead sponsor of 41 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years or older
  • Acceptance of
  • Type 1 or 2 extraction sockets (Elian et al. 2007)

Exclusion criteria

Exclusion Criteria:

  • Presence of active infection or severe inflammation in the intervention zone
  • Relevant medical history that contraindicates implant surgery
  • Patients with poor oral hygiene (full-mouth plaque score and full-mouth bleeding score >15%) and lack of motivation
  • Uncontrolled diabetes (reported levels of exceeding 7%)
  • Uncontrolled and /or untreated periodontal disease
  • Heavy smokers (more than 10 cigarettes per day)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Neobone® (Biphasic Calcium Phosphate)

    After tooth extraction the socket will be grafted with Neobone® (Biphasic Calcium Phosphate)

    Device: Neobone® (Biphasic Calcium Phosphate)

Interventions

  • DeviceNeobone® (Biphasic Calcium Phosphate)

    After tooth extraction the socket will be grafted with Neobone® (Biphasic Calcium Phosphate)

06

What researchers measure

Primary outcomes

  1. Change in alveolar ridge volume after tooth extraction

    Change in alveolar ridge volume after tooth extraction on sockets grafted with Biphasic Calcium Phosphate

    Time frame: From enrollment to the end of treatment at 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Mishchenko O, Yanovska A, Kosinov O, Maksymov D, Moskalenko R, Ramanavicius A, Pogorielov M. Synthetic Calcium-Phosphate Materials for Bone Grafting. Polymers (Basel). 2023 Sep 19;15(18):3822. doi: 10.3390/polym15183822. PubMed 37765676 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartActual
Dec 1, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07638358
Lead sponsor
Egas Moniz - Cooperativa de Ensino Superior, CRL
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Dec 1, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Angel Lobito, Masters' in Dentistry
Contact
alobito@egasmoniz.edu.pt
00351924347050
João Botelho, PhD in Biomedical Sciences
study director · Clinical Research Unit (CRU), Egas Moniz Center for Interdisciplinary Research (CiiEM), Egas Moniz School of Health & Science

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion